Fischer David, Edlow Brian L
Division of Neurocritical Care, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Center for Neurotechnology and Neurorecovery, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston.
JAMA Neurol. 2024 Mar 4. doi: 10.1001/jamaneurol.2023.5634.
Among the most impactful neurologic assessments is that of neuroprognostication, defined here as the prediction of neurologic recovery from disorders of consciousness caused by severe, acute brain injury. Across a range of brain injury etiologies, these determinations often dictate whether life-sustaining treatment is continued or withdrawn; thus, they have major implications for morbidity, mortality, and health care costs. Neuroprognostication relies on a diverse array of tests, including behavioral, radiologic, physiological, and serologic markers, that evaluate the brain's functional and structural integrity.
Prognostic markers, such as the neurologic examination, electroencephalography, and conventional computed tomography and magnetic resonance imaging (MRI), have been foundational in assessing a patient's current level of consciousness and capacity for recovery. Emerging techniques, such as functional MRI, diffusion MRI, and advanced forms of electroencephalography, provide new ways of evaluating the brain, leading to evolving schemes for characterizing neurologic function and novel methods for predicting recovery.
Neuroprognostic markers are rapidly evolving as new ways of assessing the brain's structural and functional integrity after brain injury are discovered. Many of these techniques remain in development, and further research is needed to optimize their prognostic utility. However, even as such efforts are underway, a series of promising findings coupled with the imperfect predictive value of conventional prognostic markers and the high stakes of these assessments have prompted clinical guidelines to endorse emerging techniques for neuroprognostication. Thus, clinicians have been thrust into an uncertain predicament in which emerging techniques are not yet perfected but too promising to ignore. This review illustrates the current, and likely future, landscapes of prognostic markers. No matter how much prognostic markers evolve and improve, these assessments must be approached with humility and individualized to reflect each patient's values.
最具影响力的神经学评估之一是神经预后评估,在此定义为对严重急性脑损伤所致意识障碍后神经功能恢复的预测。在一系列脑损伤病因中,这些判定通常决定是否继续或停止维持生命的治疗;因此,它们对发病率、死亡率和医疗成本具有重大影响。神经预后评估依赖于一系列不同的测试,包括行为、放射学、生理学和血清学标志物,以评估大脑的功能和结构完整性。
诸如神经学检查、脑电图以及传统计算机断层扫描和磁共振成像(MRI)等预后标志物,一直是评估患者当前意识水平和恢复能力的基础。诸如功能MRI、扩散MRI和高级形式的脑电图等新兴技术,提供了评估大脑的新方法,从而产生了不断演变的神经功能特征描述方案和预测恢复的新方法。
随着发现评估脑损伤后大脑结构和功能完整性的新方法,神经预后标志物正在迅速发展。这些技术中的许多仍在研发中,需要进一步研究以优化其预后效用。然而,即便此类研究正在进行,一系列有前景的发现,再加上传统预后标志物的预测价值不完善以及这些评估的高风险,促使临床指南认可用于神经预后评估的新兴技术。因此,临床医生陷入了一种不确定的困境,即新兴技术尚未完善,但前景太好而不容忽视。本综述阐述了预后标志物的当前及可能的未来情况。无论预后标志物如何发展和改进,进行这些评估时都必须保持谦逊,并根据个体情况进行调整,以反映每位患者的价值观。